HDACs expression in glioblastoma: an immunohistochemical study by Sferra, Roberta et al.
IJAE 
Vo l .  120 ,  n .  1  (Supp lem ent) :  27,  2015
© 2015 Firenze University Press 
ht tp://www.fupress .com/ijae
ITALIAN JOURNAL OF ANATOMY AND EMBRYOLOGY
HDACs expression in glioblastoma: an 
immunohistochemical study 
Roberta Sferra, Sara Cicchinelli, Claudio Festuccia, Luca Battistini, Simona Pompili, Antonella 
Vetuschi
Dipartimento di Scienze Cliniche Applicate e Biotecnologiche, Università degli Studi dell’Aquila, L’Aquila, Italy
Glioblastoma is the most common and lethal primary malignant brain tumor. 
Although standard treatments have been improving, the clinical outcome remains 
unacceptably poor. Several genetic alterations are supposed to be involved in the eti-
ology of different grades of astrocytoma, including epimutations. Histone deacety-
lases (HDACs) are involved in the post-translational modification on the lysines of 
histone tails. For this reason HDACs are recognized as promising targets for cancer 
treatment (1). In the past several years, HDAC inhibitors (HDACis) have been used 
as radiosensitizers in glioblastoma treatment. However, no study has demonstrated 
the status of global HDAC expression in gliomas and its possible correlation to the 
use of HDACis (2). Aim of our study was to evaluate with an immunohistochemi-
cal and immunoblotting analyses the expression of different classes of HDACs (Class 
I: HDAC 1-2-3-8; class II: HDAC 4-6) in microdissected glioblastoma. Tumor sam-
ples were taken from 14 patients (n.8 men and n.6 women) ranging in age from 43 
to 74 years. HDAC1 and HDAC3 expression was not significantly different between 
the two proteins and was predominantely located at cytoplasmic level of cancer cells 
with different intensity of immureaction from mild to moderate whereas HDAC2 
staining was localized to the nucleous of neoplastic cells. The pattern of HDAC4 
immureactivity was always cytoplasmatic and showed a marked and diffuse increase 
of immunostaining in neoplastic areas. HDAC8 was always absent in cancer cells 
and the only positivity was located in the endothelial cells of the vessels. HDAC6 
was often absent and, if present, showed a very low cytoplasmic immunopositivity 
in cancer cells. HDAC1, HDAC2 and HDAC3 levels were not significantly different 
in immunoblotting results; HDAC4 showed a marked increase while HDAC6 and 
HDAC8 expression was poor, confirming the IHC data. These previous results dem-
onstrate a different pattern of HDAC expression and could suggest a more addressed 
therapeutical use of HDACis in glioblastoma.
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